poisar

Stocks · News reference

Daxor Announces New Clinical Studies Validate BVA Technology In High-Acuity Heart Failure Populations To Enhance Care At HFSA 2026 Annual Scientific Meeting

Benzinga Newsdesk

Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DXR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

    Daxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas through its turnkey ezBVA Lab send-out model. The service provides 98% accurate blood volume measurements within 24 hours without requiring capital equipment, enabling clinicians to optimize decongestion strategies and reduce hospital readmissions.

    DXR